報價延遲最少15分鐘:2026/09/19 15:00 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.89 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.14/-4.60
|
|
企業價值
624.16M
|
| 資產負債 |
|
每股賬面淨值
4.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.84M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets. |
